Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$33.39−0.68 (-2.00%)
Close on Nov 19, 2026Market cap $2.20BP/E 6.2Yield –
Lakefront Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -€271.16M. The highest annual figure on record is €3.19B in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€271.16M | – |
| FY2024 | Dec 31, 2024 | -€336.75M | – |
| FY2023 | Dec 31, 2023 | -€424.68M | – |
| FY2022 | Dec 31, 2022 | -€527.93M | – |
| FY2021 | Dec 31, 2021 | -€558.03M | – |
| FY2020 | Dec 31, 2020 | -€469.86M | -114.7% |
| FY2019 | Dec 31, 2019 | €3.19B | – |
| FY2018 | Dec 31, 2018 | -€152.86M | – |
| FY2017 | Dec 31, 2017 | -€152.34M | -164.8% |
| FY2016 | Dec 31, 2016 | €234.95M | – |
| FY2015 | Dec 31, 2015 | -€120.69M | – |
See a number that looks wrong?